Overview

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2026-08-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
Amgen